Biocause Pharma(SZ:000627) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-14 22:44Core Points - Tianmao Industrial Group Co., Ltd. has decided to voluntarily terminate the listing of its shares through a shareholder meeting resolution, which has been approved in the first extraordinary general meeting of 2025 [2][29] - The company's stock has been suspended from trading since August 14, 2025, and will not resume trading as it enters the exercise declaration and settlement phase for cash options [2][29] - Eligible A-share shareholders will receive one cash option for each share held, with the exercise price set at 1.60 yuan per share [2][10][14] Summary by Sections Termination of Listing - The decision to terminate the listing was made during the board meeting on August 8, 2025, and was subsequently approved by the shareholders [28][29] - The company has submitted its application for termination of listing to the Shenzhen Stock Exchange on September 4, 2025, which has been accepted [29] Cash Option Details - Cash options have been distributed to eligible shareholders, totaling 1,579,130,703 options [10] - The cash option exercise period is set from September 15 to September 19, 2025, during specific trading hours [8][17] - Shareholders must declare their intention to exercise the cash options within the specified period to receive the corresponding cash compensation [3][26] Shareholder Eligibility - Eligible shareholders include all A-share shareholders registered on the cash option registration date, excluding certain parties [5] - Shareholders must ensure that their shares are not subject to restrictions such as pledges or freezes when exercising their cash options [6][20] Cash Option Execution - The cash option will not be traded on the market, and the exercise will be conducted through the Shenzhen Stock Exchange's trading system [11][16] - The value of the cash options is calculated at 0.15 yuan, with a Delta value of -0.4759, indicating a slight premium over the current stock price [15]